Huang Changsheng, Jin Hongyan
Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China.
Chin Med J (Engl). 2024 Jan 8;137(18):2157-68. doi: 10.1097/CM9.0000000000002889.
Breast cancer, a malignant tumor with a high incidence in women, lacks in vitro research models that can represent the biological functions of breast tumors in vivo. As a new biological tool, the organoid model has unique advantages over traditional methods, such as cell culture and patient-derived xenografts. Combining organoids with other emerging technologies, such as gene engineering and microfluidic chip technology, provides an effective method to compensate for the deficiencies in organoid models of breast cancer in vivo. The emergence of breast cancer organoids has provided new tools and research directions in precision medicine, personality therapy, and drug research. In this review, we summarized the merits and demerits of organoids compared to traditional biological models, explored the latest developments in the combination of new technologies and organoid models, and discussed the construction methods and application prospects of different breast organoid models.
乳腺癌是女性中发病率较高的恶性肿瘤,缺乏能够在体外代表乳腺肿瘤体内生物学功能的研究模型。作为一种新的生物学工具,类器官模型相对于传统方法,如细胞培养和患者来源的异种移植,具有独特的优势。将类器官与其他新兴技术,如基因工程和微流控芯片技术相结合,为弥补乳腺癌类器官模型在体内的不足提供了一种有效的方法。乳腺癌类器官的出现为精准医学、个性化治疗和药物研究提供了新的工具和研究方向。在这篇综述中,我们总结了类器官相对于传统生物学模型的优缺点,探讨了新技术与类器官模型相结合的最新进展,并讨论了不同乳腺类器官模型的构建方法和应用前景。